Literature DB >> 9291185

Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.

F S Shihab1, W M Bennett, A M Tanner, T F Andoh.   

Abstract

Angiotensin II (Ang II) is implicated in fibrosis but the precise mechanism of this effect remains unclear. In a model of chronic cyclosporine (CsA) nephropathy, we previously showed that TGF-beta1 plays a role in CsA-induced tubulointerstitial fibrosis and arteriolopathy by stimulating extracellular matrix (ECM) protein synthesis and inhibiting ECM degradation through increasing the synthesis of plasminogen activator inhibitor (PAI)-1. We hypothesized that Ang II contributes to fibrosis by inducing TGF-beta1. Salt-depleted rats were given placebo, CsA alone, CsA + nilvadipine, CsA + hydralazine/hydrochlorthiazide, CsA + losartan (AT1 receptor antagonist) or CsA + enalapril (Ang converting enzyme inhibitor) and were sacrificed at 7 and 28 days. All treated groups achieved similar blood pressures and glomerular filtration rates. The lesion of chronic CsA nephropathy was ameliorated by concomitant therapy with losartan or enalapril at 28 days, a phenomenon not observed in the other treatment groups. Similarly, Ang II blockade resulted in decreased expression of TGF-beta1 and PAI-1 by Northern and ELISA. Similarly, the expression of ECM proteins directly influenced by TGF-beta decreased with Ang II blockade. These results suggest that CsA-induced fibrosis in this model is independent of renal hemodynamics and is mediated, at least partly, through Ang II induction of TGF-beta1 expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291185     DOI: 10.1038/ki.1997.380

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

Review 1.  A practical guide to the management of hypertension in renal transplant recipients.

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  2006 Curt Stern Award Address. Marfan syndrome: from molecules to medicines.

Authors:  Harry C Dietz
Journal:  Am J Hum Genet       Date:  2007-10       Impact factor: 11.025

Review 4.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

5.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Ding-Guo Li; Han-Ming Lu; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Jing Zhang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 6.  TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Authors:  Elena Gallo MacFarlane; Julia Haupt; Harry C Dietz; Eileen M Shore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 7.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

8.  Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis.

Authors:  Jennifer L Faulkner; Lisa M Szcykalski; Fredyne Springer; Jeffrey L Barnes
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 9.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

10.  Kidney fibrosis in hypertensive rats: role of oxidative stress.

Authors:  Wenyuan Zhao; Sue S Chen; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Am J Nephrol       Date:  2008-02-01       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.